Search clinical trials for: hemophilia A

Total 498429 results

Prometic Biotherapeutics, Inc.

Completed

A Study of Prometic Plasminogen IV Infusion in Subjects With Hypoplasminogenemia

Hypoplasminogenemia | Congenital Plasminogen Deficiency

United States, Norway
Volkan Deniz, PT

Completed

The Effects of Therapeutic Exercises on Kinesiophobia in Haemophilic Patients.

Haemophilia

Turkey
Pfizer

Completed

PF-06741086 Long-term Treatment in Severe Hemophilia

Hemophilia A or B

Poland, Switzerland, South Africa, United States, Croatia, Brazil, Chile
Nantes University Hospital

Completed

Hemophilia and Bone Metabolism: Study of Monocytic Populations and Inflammatory Proteins (BOHEM)

Hemophilia | Arthropathy | Osteopenia

France
Bio Products Laboratory

Terminated

Post-Marketing Safety Study Following Long-Term Prophylactic OptivateTreatment in Subjects With Severe Haemophilia A

Haemophilia A

Colombia, Germany, Poland
Assiut University

Completed

Dexmedetomidine to Levobupivacaine for Transversus Abdominis Plane Block in Elderly Patients Undergoing Inguinal Hernia Repair Surgery

Dexmedetomidine | Fentanyl

Egypt
Assiut University

Completed

Single-shot Adductor Canal Block With Levobupivacaine and Dexmedetomidine in Total Knee Arthroplasty

Dexmedetomidine | Levobupivacaine | Adductor Canal Block

Egypt
Hospices Civils de Lyon

Completed

Medication Exposure in Older Patients With Constitutional Hemorrhagic Disease (M-HEMORRH'AGE)

Hemophilia

France
National Taiwan University Hospital

Terminated

Intra-articular Bevacizumab for Recurrent Hemarthroses at Target Joints With Chronic Hemophilic Synovitis

Hemophilia | Synovitis

Taiwan
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors (HAVEN 1)

Hemophilia A

Korea, Republic of, United States, France, Germany, Italy, South Africa, Spain, Japan, United Kingdom, Poland, Taiwan, Australia, Costa Rica, New Zealand
Hoffmann-La Roche

Completed

A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors (STASEY)

Hemophilia A

Canada, Australia, Belgium, India, Germany, Israel, Italy, Spain, Colombia, United Kingdom, Netherlands, Saudi Arabia, Hungary, Guatemala, Russian Federation, Poland, Switzerland, Finland, Panama, Brazil, Mexico, Portugal, Romania, Sw...
Baxalta now part of Shire

Completed

Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A

Hemophilia A

United States
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors (HAVEN 2)

Hemophilia A

United States, France, Germany, Italy, South Africa, Spain, Turkey, Japan, United Kingdom, Costa Rica
Baxalta now part of Shire

Completed

BAX 826 Dose-Escalation Safety Study

Hemophilia A

Spain, Bulgaria, Germany, United Kingdom, Italy, Poland, Russian Federation, Netherlands, Hungary
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

BAX 855 PK-guided Dosing (PROPEL)

Hemophilia A

Spain, United States, Australia, Singapore, Taiwan, Hong Kong, Malaysia, Bulgaria, United Kingdom, Switzerland, Ukraine, Turkey, Italy, Norway, France, Austria, Romania, Sweden, Poland, Germany, Hungary, Israel
Skane University Hospital
Indiana Hemophilia &Thrombosis Center, Inc.; Bioverativ Therapeutics Inc.; Swedish...

Active, not recruiting

Natural History Study of Factor IX Treatment and Complications (B-Natural)

Factor IX Deficiency

United States
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

BAX 855 Continuation

Hemophilia A

United States, Spain, Netherlands, Australia, Czechia, Korea, Republic of, Taiwan, Poland, Bulgaria, United Kingdom, Germany, Turkey, Israel, Malaysia, Ukraine, Russian Federation, Austria, Switzerland, Japan, Hong Kong, Lithuania, Roman... and more
Baxalta now part of Shire

Completed

Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures

Hemophilia A

United States, Spain, Netherlands, United Kingdom, Bulgaria, Lithuania, Russian Federation, Switzerland, Ukraine
Baxalta now part of Shire
Baxter Innovations GmbH

Terminated

Early Prophylaxis Immunologic Challenge (EPIC) Study (EPIC)

Hemophilia A

Poland, United States, Bulgaria, Serbia, Canada, Russian Federation, Germany, Netherlands, Lithuania, Czechia, Austria, Spain
Baxalta now part of Shire

Completed

Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients

Hemophilia A

United States, France, United Kingdom, Spain, Germany, Canada, Puerto Rico, Italy, Sweden, Austria
Baxalta now part of Shire

Completed

Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for Injection

Hemophilia A

United States
Baxalta now part of Shire

Completed

BAX 855 Pediatric Study

Hemophilia A

United States, Spain, United Kingdom, Taiwan, Malaysia, Bulgaria, Hong Kong, Korea, Republic of, Netherlands, Turkey, Ukraine
Shire

Approved for marketing

Treatment Protocol of Velaglucerase Alfa for Patients With Type 1 Gaucher Disease

Gaucher Disease, Type 1

United States
Baxalta now part of Shire

Completed

BAX 326 Pediatric Study

Hemophilia B

Russian Federation, Ukraine, India, Poland, Romania, United Kingdom
OPKO Health, Inc.

Completed

A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B

Hemophilia A | Hemophilia B

United States
Baxalta now part of Shire

Completed

BAX 326 (rFIX) Continuation Study

Hemophilia B

Taiwan, Colombia, Argentina, Brazil, Bulgaria, Chile, Czechia, India, Ireland, Italy, Japan, Poland, Romania, Russian Federation, Sweden, Ukraine, United Kingdom
Baxalta now part of Shire

Completed

Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study)

Hemophilia A

United States, Spain, Netherlands, Australia, Czechia, Korea, Republic of, Poland, Germany, Taiwan, Israel, Ukraine, United Kingdom, Malaysia, Japan, Austria, Switzerland, Sweden, Bulgaria, Lithuania, Romania
Baxalta now part of Shire

Completed

Pivotal Study (Pharmacokinetics, Efficacy, Safety) of BAX 326 (rFIX) in Hemophilia B Patients

Hemophilia B

Poland, United Kingdom, Spain, Bulgaria, Romania, Japan, Russian Federation, Brazil, Chile, Sweden, Colombia, Ukraine, Argentina, Czechia
Baxalta now part of Shire

Completed

Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)

Von Willebrand Disease

Netherlands, Spain, United States, Belgium, Australia, United Kingdom, Austria, Italy, Bulgaria, Japan, Poland, Germany, India, Canada, Russian Federation, Sweden
Baxalta now part of Shire

Completed

Pharmacokinetic Study of ADVATE 3000 IU in Previously Treated Patients With Severe Hemophilia A

Hemophilia A

Bulgaria, Russian Federation
Baxalta now part of Shire

Completed

Prophylaxis Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A

Hemophilia A

United States, Poland, Slovenia, Greece, Russian Federation, Hungary, Italy, United Kingdom, Czechia, Austria
Baxalta now part of Shire

Completed

Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor

Hemophilia A | Hemophilia B | Hemophilia A or B With Inhibitors

Poland, United States, Bulgaria, Romania, Japan, Russian Federation, New Zealand, Croatia, Ukraine, Brazil
Baxalta now part of Shire

Completed

Recombinant Von Willebrand Factor in Subjects With Severe Von Willebrand Disease Undergoing Surgery

Von Willebrand Disease

United States, Spain, Australia, Taiwan, Czechia, Turkey, Ukraine, Netherlands, Italy, United Kingdom, Austria, Germany, Russian Federation
Baxalta now part of Shire

Completed

Pharmacokinetic Comparison of Advate rAHF-PFM With Recombinate rAHF in Patients With Severe Hemophilia A

Hemophilia A

Germany
Baxalta now part of Shire

Completed

BAX 326 Surgery Study in Hemophilia B Patients

Hemophilia B

Colombia, Bulgaria, Chile, Poland, Romania, Argentina, Czechia, Russian Federation, Ukraine, United Kingdom
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery

Hemophilia A

United States, Belgium, France, Norway, Netherlands, Austria, Hungary, Italy, Poland, Portugal, Romania, Russian Federation, Spain, Sweden
Baxalta now part of Shire

Terminated

Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Congenital Hemophilia A

Hemophilia A

United States, South Africa, United Kingdom
RESCUe - RESeau Cardiologie Urgence / RESUVal -...
Hospices Civils de Lyon

Unknown

Accessibility of Prophylaxis and On-demand Treatment for Persons With Haemophilia and Other Coagulation Deficiencies (PHAREO)

Health Services Accessibility | Blood Coagulation Factor Deficiencies

France
Baxalta now part of Shire

Completed

Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A

Acquired Hemophilia A

United States, Canada, India, United Kingdom
Baxalta now part of Shire

Completed

Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen

Hemophilia A | Hemophilia B

Japan, Russian Federation, Spain, United States, Poland, Romania, Serbia, Taiwan, Ukraine
Haemnet
Roche Chugai

Completed

An Exploration of the Impact of Emicizumab on the Lives of People With Haemophilia and Inhibitors and Their Families (EmiandMe)

Hemophilia A With Inhibitor

United Kingdom
Baxalta now part of Shire

Completed

Efficacy and Safety Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients in Canada With Hemophilia A - A Continuation of Baxter Study 060101

Hemophilia A

Canada
Baxalta now part of Shire

No longer available

Expanded Access to B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies

Acquired Hemophilia A

United States
Baxalta now part of Shire

Completed

Post-Marketing Surveillance (Usage Results Study) of RIXUBIS in Adult and Pediatric Patients With Haemophilia B in South Korea

Hemophilia B

Korea, Republic of
Baxalta now part of Shire
Baxter Innovations GmbH

Completed

BAX 855 Dose-Escalation Safety Study

Hemophilia A

Japan, Bulgaria, Germany, United Kingdom
Baxalta now part of Shire

Terminated

First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients

Hemophilia

United Kingdom
Pfizer

Completed

Moroctocog Alfa (AF-CC) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Hemophilia A Patients

Hemophilia A

India
Baxalta now part of Shire

Completed

China ADVATE PTP Study

Hemophilia A

China
Baxalta now part of Shire

Completed

Pharmacokinetic, Safety and Tolerability Study of Recombinant Von Willebrand Factor / Recombinant Factor VIII Complex in Type 3 Von Willebrand Disease

Von Willebrand Disease

United States, Germany, United Kingdom, Italy, Austria, Canada
Baxalta now part of Shire

Completed

Pharmacokinetics, Efficacy and Safety Study of IMMUNATE SD (Human Plasma-Derived Coagulation Factor VIII Concentrate) in Hemophilia A Patients

Hemophilia A

Czechia, Bulgaria, Hungary, Poland

Search clinical trials for: hemophilia A

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malawi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations